Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults

Ruth Link‐Gelles; Elizabeth Rowley; Stephanie A. Irving; Nicola P. Klein; Shaun J. Grannis; Toan C. Ong; Sarah W. Ball; Malini B. DeSilva; Kristin Dascomb; Allison L. Naleway; Pradeep Koppolu; Ousseny Zerbo; Bruce Fireman; John Hansen; Julius Timbol; Lawrence Block; Brian E. Dixon; Thomas J. Duszynski; Katie Allen; David Mayer; Catia Chávez; Michelle A. Barron; Sarah E. Reese; Sean Chickery; Jonathan M. Davis; Allison Avrich Ciesla; Josephine Mak; Morgan Najdowski; Omobosola Akinsete; Charlene McEvoy; Inih Essien; Tamara Sheffield; Daniel Bride; Julie Arndorfer; Joshua Van Otterloo; Karthik Natarajan; Mark W. Tenforde; Jennifer DeCuir; Amanda B. Payne

doi:10.1001/jamanetworkopen.2025.17402

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In this case-control study of VE, 2023-2024 COVID-19 vaccines were estimated to provide additional effectiveness against medically attended COVID-19, with the highest and most sustained estimates against critical illness. These results highlight the importance of receiving recommended COVID-19 vaccination for adults 18 years or older.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Link‐Gelles et al. (2025) studied this question.

synapsesocial.com/papers/69dabecd7a67537a8ba3c4de https://doi.org/10.1001/jamanetworkopen.2025.17402

View Full Paper

Ask AI

Bookmark

Share

Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults

Ask about this paper

Abstract

Discussion

Cite This Study

Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading